Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
3.
Rev Mal Respir ; 25(7): 885-93, 2008 Sep.
Article in French | MEDLINE | ID: mdl-18946418

ABSTRACT

BACKGROUND: After stopping a 3 to 6 months course of oral anticoagulation for a first episode of idiopathic venous thromboembolism (VTE), the risk of recurrent VTE is high (10% per year). In this setting, international guidelines recommend at least 6 months treatment. However, this recommendation is not satisfactory for the following reasons: (1) no randomized trial has compared 6 months to extended duration (2 years) anticoagulation; and (2), even though the frequency of recurrent VTE is similar after pulmonary embolism (PE) and deep vein thrombosis (DVT), the fatality rate of recurrent VTE after PE is higher than that after DVT. METHODS: A French multicentre double blind randomized trial. The main objective is to demonstrate, after a first episode of symptomatic idiopathic PE treated for 6 months using a vitamin K antagonist, that extended anticoagulation for 18 months (INR between 2 and 3) is associated with an increased benefit / risk ratio (recurrent VTE and severe anticoagulant-related bleeding) compared to placebo. The double blind evaluation is ensured using by active warfarin and placebo, and blinded INR. The protocol was approved by the ethics board of the Brest Hospital on the 7th of March 2006. For an alpha risk of 5% and a beta risk of 20%, the estimated sample size is 374 patients. EXPECTED RESULTS: This study has the potential to: (1) demonstrate that the benefit / risk ratio of extended anticoagulation for 18 months is higher than that observed with placebo in patients with a first episode of idiopathic PE initially treated for 6 months, during and after the treatment period; and (2) to validate or invalidate the contribution of isotope lung scans, lower limb Doppler ultrasound and D-Dimer at 6 months of treatment as predictors of recurrent VTE (medico-economic analysis included).


Subject(s)
Anticoagulants/therapeutic use , Pulmonary Embolism/drug therapy , Venous Thromboembolism/drug therapy , Vitamin K/antagonists & inhibitors , Warfarin/therapeutic use , Anticoagulants/administration & dosage , Anticoagulants/adverse effects , Chi-Square Distribution , Data Interpretation, Statistical , Double-Blind Method , Hemorrhage/chemically induced , Humans , Placebos , Practice Guidelines as Topic , Prognosis , Recurrence , Risk Assessment , Time Factors , Warfarin/administration & dosage , Warfarin/adverse effects
5.
Haemophilia ; 8(5): 639-43, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12199672

ABSTRACT

Assay of factor VIII (FVIII) in patient samples is routinely carried out using the one-stage assay rather than the chromogenic substrate assay. The introduction of new FVIII preparations for the treatment of haemophilia A, including immunopurified FVIII and particularly, recombinant FVIII (rFVIII) concentrates, has led to discrepancies between the results obtained with the two assays. In patients treated with rFVIII concentrates, FVIII levels measured with the one-stage assay can be 20-50% lower than those measured with the chromogenic assay. In this study, the one-stage assay was performed with cephalin dilutions higher than those recommended by the manufacturer. B-domain-deleted recombinant FVIII, Refacto, was diluted to eight different concentrations, ranging from 1-100 IU dL(-1), in FVIII-deficient plasma and the FVIII activity of the eight solutions was determined by the chromogenic method in a central laboratory. Aliquots were then assayed by the one-stage method in the four participating laboratories, using different dilutions of CK-Prest. When CK-Prest was reconstituted according to the manufacturer's recommendations (dilution 1 : 1), the difference between the one-stage and chromogenic methods was close to 30%. CK-Prest cephalin dilutions of 1 : 5 and 1 : 8 gave very similar results with the two methods, without increasing the interlaboratory coefficient of variation. These findings confirm the influence of phospholipids on the one-stage assay, particularly the importance of using a phospholipid concentration close to the physiological value in platelets. This modified one-stage method may therefore offer an alternative to the use of a concentrate-specific standard.


Subject(s)
Factor VIII/analysis , Hematologic Tests , Chromogenic Compounds , Factor VIII/therapeutic use , Hemophilia A/blood , Hemophilia A/drug therapy , Humans , Partial Thromboplastin Time , Phosphatidylethanolamines , Pilot Projects , Recombinant Proteins/therapeutic use , Regression Analysis , Sensitivity and Specificity , Single-Blind Method
6.
Blood Coagul Fibrinolysis ; 13(5): 465-70, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12138376

ABSTRACT

The common genetic G to A variation of the prothrombin gene is associated with elevated levels of prothrombin [factor II (FII)] and is recognized as a risk factor for thrombosis. To determine whether one type of assay for plasma FII measurement was more efficient than other assays in displaying high FII levels in 20210A carriers, we compared five methods of measuring FII levels [i.e. an enzyme-linked immunosorbent assay (ELISA), a standard clotting assay, and three chromogenic methods using three different activators: Ecarin, Oxyuranus, and Textarin] in 30 G20210A patients and 30 G20210G controls. Plasma concentrations of factor X and factor VII + factor X were also determined by a clotting procedure. Functional assays were found to be equally efficient in demonstrating significantly higher FII levels in 20210A carriers than in non-carriers (P < 0.0001). With ELISA, the difference observed was less significant (P < 0.005). The specificity of every assay increased with FII cut-off levels; when a cut-off of 115% was applied, sensitivities of functional assays were between 73 and 93%, while sensitivities of ELISA declined dramatically to 33%. FII/factor X and FII/factor VII + factor X ratios were significantly higher in 20210A carriers (P < 0.0001). In conclusion, functional assays are preferentially required for measurements of FII levels in carriers of the 20210A variant.


Subject(s)
3' Untranslated Regions/genetics , Polymorphism, Genetic , Prothrombin/analysis , Thrombophilia/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Area Under Curve , Blood Coagulation Tests , Child , Child, Preschool , Chromogenic Compounds , Elapid Venoms/pharmacology , Endopeptidases/pharmacology , Enzyme Activation/drug effects , Enzyme-Linked Immunosorbent Assay , Factor VII/analysis , Factor X/analysis , Female , Genotype , Humans , Male , Middle Aged , Prothrombin/genetics , ROC Curve , Sensitivity and Specificity , Serine Endopeptidases/pharmacology , Thrombophilia/blood
7.
Presse Med ; 31(1 Pt 1): 13-8, 2002 Jan 12.
Article in French | MEDLINE | ID: mdl-11826576

ABSTRACT

OBJECTIVE: Ventilation/perfusion pulmonary scintigraphy (PS), the current mainspring in the diagnosis of pulmonary oedema (PE), is frequently non-conclusive. The objective of this study was to determine, prospectively, the diagnostic value of the association of D-dimers and helicoidal thoracic scanner (HTS) in a continuous series of ambulatory adults with suspected PE and admitted to a cardiologic emergency unit. METHODS: Exclusion criteria were as follows: symptoms or clinical signs of seventy, contraindication for HTS and/or on pulmonary angiography, curative anticoagulant therapy for more than 48 hours, history of PE less than 3 months before or the impossibility of conducting all the examinations with 48 hours. All the patients underwent determination of D-dimers by rapid ELISA test, HTS and 2 reference examinations, venous Doppler of the lower limbs and a PS, completed by pulmonary angiography if the PS did not permit diagnosis and the venous Doppler was negative. RESULTS: One hundred and six patients were selected over a recruitment period of 18 months. The prevalence of PE was of 45% (48/106). Forty-four of the 48 PE of the series were central form. HTS was considered dubious in 10 patients (10.4%, PE+ n = 2, PE- n = 8). The results of D-dimers were negative in only 34.5% patients without PE (20/58). Pulmonary angiography was necessary in 15 patients. The negative and positive predictive values of D-dimers were respectively of 100 and 55.8% (48/86) and those of HTS respectively 100 (46/46) and 92% (46/50). CONCLUSION: The diagnostic strategy of clinical suspicion of PE, starting with determination of D-dimers by rapid ELISA test followed by helicoidal thoracic scanner in the case of a positive result, was particularly effective in this series of patients with a high prevalence of PE. These results must be confirmed in a larger series and in a general emergency unit.


Subject(s)
Pulmonary Embolism/blood , Pulmonary Embolism/diagnostic imaging , Adult , Aged , Aged, 80 and over , Ambulatory Care , Dimerization , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Prospective Studies , Pulmonary Embolism/diagnosis , Radiography
8.
Thromb Haemost ; 86(2): 584-9, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11522007

ABSTRACT

Quantification of lupus anticoagulant (LA) in clinical samples is hampered by the lack of a suitable standard of activity. We evaluated the use of mAbs displaying LA activity for this purpose. As most patient samples contain both beta2Glycoprotein I (beta2GP1) and prothrombin dependent LA, a combination of two mAbs, one of each specificity, was added to normal plasma in a concentration from 0 to 60 microg/ml. Eight assay systems using different reagents and instruments were used. The calibration curves were linear for all but one, with marked differences between the responsiveness to each mAb. A panel of plasmas from 69 patients with persistent LA diagnosed using the SSC-ISTH criteria was tested. An antiphospholipid syndrome (APS) was present in 40, whereas 29 were asymptomatic. LA activities of individual plasmas varied between assays (p < 10(-4)), but homogeneous subgroups were identified. In a majority of samples, LA activity displayed a prothrombin-dependent profile, with a variable contribution of beta2GP1-dependent activity. The latter was associated to beta2GP1 antibodies detected by solid-phase immunoassay. By using 3 dilute Russell viper venom time assays, higher LA titers were found in APS, compared to asymptomatic patients (p <0.05).


Subject(s)
Antibodies, Monoclonal , Glycoproteins/immunology , Lupus Coagulation Inhibitor/blood , Prothrombin/immunology , Adult , Antiphospholipid Syndrome/diagnosis , Antiphospholipid Syndrome/etiology , Antiphospholipid Syndrome/immunology , Autoantibodies/blood , Autoantibodies/classification , Blood Coagulation Tests , Calibration , Female , Glycoproteins/pharmacology , Humans , Immunoassay/standards , Immunoglobulin G/blood , Immunoglobulin M/blood , Lupus Coagulation Inhibitor/classification , Lupus Coagulation Inhibitor/immunology , Male , Sensitivity and Specificity , beta 2-Glycoprotein I
9.
Blood Coagul Fibrinolysis ; 12(1): 59-66, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11229828

ABSTRACT

The effects of alcohol withdrawal on fibrinolysis were studied in 10 middle-aged male chronic alcoholics institutionalized for withdrawal therapy. All patients were sampled on admission [day 1 (D1)] and 21 days after alcohol withdrawal [day 22 (D22)]. The overall plasma fibrinolytic capacity (OFC) was assayed by measuring the ability of patient plasma to generate D-dimers from a standardized fibrin clot, and tissue-type plasminogen activator (t-PA) and t-PA inhibitor (PAI-1) levels were assayed together with serum cholesterol, triglyceride and cholesterol fractions. At D22, the OFC significantly increased in seven patients [D1 = 10 +/- 0.7 microg/h (mean +/- SD), D22 = 17 +/- 7.4 microg/h; P < 0.01], while t-PA and PAI-1 levels decreased in all patients but two (t-PA: D1 = 16.6 +/- 5 ng/ml, D22 = 10.2 +/- 3.8 ng/ml; P < 0.001; and PAI-1: D1 = 46 +/- 39 ng/ml, D22 = 21 +/- 28 ng/ml; P < 0.01). This study clearly demonstrates an increase in overall fibrinolytic activity after alcohol withdrawal, which is mainly due to a decrease in PAI-1 levels. These changes induced by alcohol abstinence might provide clear benefit by reducing the risk of thromboembolic events and particularly of stroke associated with elevated PAI-1 levels described in heavy drinkers.


Subject(s)
Alcoholism/blood , Ethanol/adverse effects , Fibrinolysis/drug effects , Plasminogen Inactivators/blood , Substance Withdrawal Syndrome/blood , Tissue Plasminogen Activator/blood , Adult , Hemostasis/drug effects , Humans , Lipids/blood , Male , Middle Aged , Prospective Studies , Statistics, Nonparametric , Tissue Plasminogen Activator/antagonists & inhibitors
12.
Am J Clin Pathol ; 111(5): 700-6, 1999 May.
Article in English | MEDLINE | ID: mdl-10230362

ABSTRACT

The value of the platelet aggregation test, carbon 14-labeled serotonin release assay (SRA), and heparin-platelet factor 4 enzyme-linked immunosorbent assay (H-PF4 ELISA) for the diagnosis of heparin-induced thrombocytopenia was evaluated by studying blood samples from 100 patients with suspected heparin-induced thrombocytopenia, and categorized into 4 clinical groups: unlikely (n = 22), possible (34), probable (36), and definite (8) thrombocytopenia. Results of the platelet aggregation test were positive in 40 of 44 patients with probable or definite heparin-induced thrombocytopenia (sensitivity 91%) and in 5 of 22 unlikely to have heparin-induced thrombocytopenia (specificity 77%). The SRA exhibited sensitivity of 88% and negative predictive value of 81%, close to those values for the platelet aggregation test; specificity and positive predictive value were 100%. The sensitivity of the heparin-PF4 ELISA was 97%, with specificity 86%, and a positive correlation was recorded between the level of antibodies to H-PF4 and clinical score (P = 0.66). When ELISA was used with the platelet aggregation test or SRA, positive predictive value and specificity were 100% when both tests yielded positive results, and negative predictive value was 100% when both tests yielded negative results. A biologic flow chart was designed that presented a choice based on the results of the platelet aggregation test or SRA in association with ELISA, and enabled more accurate and specific identification of heparin-induced thrombocytopenia.


Subject(s)
Clinical Laboratory Techniques , Decision Support Techniques , Enzyme-Linked Immunosorbent Assay/methods , Heparin/adverse effects , Thrombocytopenia/chemically induced , Thrombocytopenia/diagnosis , Carbon Radioisotopes , Heparin/metabolism , Humans , Platelet Aggregation , Platelet Factor 4/metabolism , Predictive Value of Tests , Sensitivity and Specificity , Serotonin/metabolism , Thrombocytopenia/metabolism
14.
Thromb Haemost ; 80(1): 99-103, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9684793

ABSTRACT

The recommended therapeutic range of International Normalized Ratio (INR) for oral anticoagulant treatment in patients with the antiphospholipid syndrome remains controversial. As a part of this controversy, it has been suggested that lupus anticoagulants (LA) could interfere with the determination of prothrombin time, thus questioning the validity of monitoring the treatment of these patients using INR. To clarify this point, we compared the values of INR obtained in the plasmas of two groups of patients, one without LA (n = 47), and the other with LA (n = 43). INR were determined using 8 different thromboplastin reagents on the same automated coagulation instrument. Chromogenic factor X, which is supposed to be insensitive to the presence of LA, was also measured. The results are the following: provided INR was calculated using calibrated reference plasmas, there was no significant difference between INR values obtained with the 8 reagents, both in the non-LA and in the LA groups (CV: 5.9 and 6.7%. respectively). Closer examination revealed that INR results obtained with one reagent (the recombinant thromboplastin Innovin) diverged from those of the 7 others, leading to an overestimation of INR, to a very large extent in some instances. However this effect was restricted to a subset of the patient population with LA (6 out of 43). Finally, the relationship between INR (average value obtained using the 8 reagents) and factor X was identical in non-LA and in LA patient groups. We conclude that, provided the reagents which display the LA interference are identified and excluded for this purpose, the INR system is valid for monitoring oral anticoagulant treatment in patients with LA.


Subject(s)
Antiphospholipid Syndrome/drug therapy , Lupus Coagulation Inhibitor/therapeutic use , Administration, Oral , Animals , Cattle , Humans , International Normalized Ratio
15.
Br J Haematol ; 99(2): 273-80, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9375738

ABSTRACT

Heparin-induced thrombocytopenia (HIT) is frequently associated with antibodies (Abs) to heparin-PF4 complexes (H-PF4). In order to investigate whether there are variations in specificity of Abs, we studied 63 samples from patients with suspected HIT. Two groups of samples were separated after comparing their reactivity against H-PF4 or recombinant PF4 (r-PF4) using ELISA. In group Ab1 (n = 46), Abs only or mainly bound to H-PF4 complexes and thus most of the epitopes recognized probably involved both heparin and PF4. In group Ab2 (n = 17), Abs exhibited similar reactivity to r-PF4 and H-PF4, and the antigens recognized were possibly neoepitopes mainly expressed by modified PF4 and by H-PF4 complexes. Platelet activation tests were positive with 56 samples containing high titres of Abs to H-PF4. Most samples (n = 59) contained IgG antibodies, often associated with IgA antibodies which were more frequently found in group Ab2, and/or IgM. With unfractionated heparin treatment, HIT was associated with Ab1 or Ab2 antibodies, whereas only Ab1 antibodies were detected after low-molecular-weight heparin (LMWH). Furthermore, cross-reactivity with danaparoid sodium was present only in group Ab1 and mainly involved LMWH-treated patients.


Subject(s)
Antibodies/immunology , Chondroitin Sulfates/immunology , Dermatan Sulfate/immunology , Heparin/immunology , Heparitin Sulfate/immunology , Thrombocytopenia/immunology , Adult , Aged , Aged, 80 and over , Antibody Specificity , Drug Combinations , Enzyme-Linked Immunosorbent Assay , Female , Heparin/adverse effects , Humans , Interleukin-8/immunology , Male , Middle Aged , Peptides/immunology , Platelet Activation , Platelet Factor 4/immunology , Thrombocytopenia/chemically induced , beta-Thromboglobulin
16.
Blood Coagul Fibrinolysis ; 8(8): 503-9, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9491268

ABSTRACT

The laboratory diagnosis of activated protein C (APC) resistance is based on a weak anticoagulant response to APC using a chronometric procedure confirmed in almost all cases by molecular diagnosis of the FV Leiden mutation. A recently-developed Xa-based assay (Accelerimat, Biomerieux) was compared with two different activated partial thromboplastin time (APTT)-based procedures (Coatest APC resistance and Modified Coatest, Chromogenix) in 115 patients with a personal or familial history of thrombotic disease, or both, being studied for the FV Leiden mutation. Our results confirmed the improvement in specificity for the FV Leiden mutation when the APTT-based assay was performed after dilution of samples in FV-deficient plasma (Modified Coatest). However, five patients who were heterozygous for the FV Leiden mutation appeared to be homozygous when tested by both APTT-based assays. These patients, belonging to three different families, had a FV type I deficiency with FV plasma levels between 43 and 64%. In contrast, the Xa-based method was not influenced by the decrease in plasma FV levels. Thus, this procedure is more specific than APTT-based assays to predict the genotype status of the FV Leiden mutation.


Subject(s)
Factor V Deficiency/genetics , Factor V/genetics , Heterozygote , Homozygote , Point Mutation , Protein C/physiology , Adolescent , Adult , Aged , Aged, 80 and over , Amino Acid Substitution , Arginine/analysis , Blood Coagulation Disorders/genetics , Case-Control Studies , Child , Female , Glutamine/analysis , Humans , Male , Middle Aged , Pedigree
17.
Blood ; 88(3): 900-6, 1996 Aug 01.
Article in English | MEDLINE | ID: mdl-8704247

ABSTRACT

Blood coagulation proteins were determined in 285 healthy fetuses from 19 to 38 weeks' gestation and compared with those of 60 normal full-term newborns and 40 adult controls. Prolongation of the coagulation screening tests, prothrombin time, activated partial prothrombin time, and thrombin clotting time, in fetuses throughout intrauterine life was explained by low levels of vitamin K-dependent factors (II, VII, IX, and X), contact factors (XI, XII, prekallikrein, and high-molecular-weight kininogen), factor V, factor VIII, and fibrinogen. Low levels of antithrombin III, heparin cofactor II, protein C and protein S, and tissue factor pathway inhibitor were also found, and these probably contributed to a satisfactory hemostatic balance. Some of these parameters were evaluated by both immunologic and functional assays to detect possible "fetal" proteins. An increase in factor levels was observed after the thirty-fourth week of intrauterine life for most of the coagulation activators and inhibitors, but only factors V and VIII reached adult values at birth. This study therefore showed that fetal hemostasis is a dynamic system that evolves gradually toward the neonatal state and then toward the adult state.


Subject(s)
Blood Coagulation Factors/analysis , Blood Coagulation/physiology , Blood Proteins/analysis , Fetal Blood/physiology , Adult , Antithrombins/analysis , Gestational Age , Heparin Cofactor II/analysis , Humans , Infant, Newborn , Lipoproteins/analysis , Prenatal Diagnosis , Protein C/analysis , Protein S/analysis , Reference Values , Umbilical Veins , Vitamin K/analysis
18.
Ann Vasc Surg ; 5(6): 552-5, 1991 Nov.
Article in English | MEDLINE | ID: mdl-1722991

ABSTRACT

Heparin-associated thrombocytopenia and thrombosis is a severe complication of systemic heparin therapy. Its treatment is mainly based upon discontinuation of heparin therapy. However in some patients requiring emergency cardiac or vascular surgery, reexposure to heparin may be unavoidable. We report the management of two such patients by use of antiplatelet drugs for a vascular procedure. In the two cases, a combination of iloprost, a stable prostacyclin analogue (1 to 2 ng/kg/mn) with aspirin and dipyridamole was shown to inhibit ex vivo the heparin-induced platelet aggregation. These antiplatelet agents were continued during the perioperative period. A successful vascular procedure was achieved with full heparinization without subsequent thrombocytopenia or thrombotic or hemorrhagic complications. This experience supports the hypothesis that heparin can be readministered early to patients with heparin-associated thrombocytopenia and thrombosis, provided antiplatelet therapy is given.


Subject(s)
Aspirin/therapeutic use , Dipyridamole/therapeutic use , Heparin/adverse effects , Iloprost/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Thrombocytopenia/chemically induced , Thrombocytopenia/drug therapy , Thrombosis/chemically induced , Thrombosis/drug therapy , Aged , Aorta, Abdominal , Female , Femoral Vein , Humans , Iliac Artery , Iliac Vein , Ischemia/drug therapy , Platelet Aggregation/drug effects , Vena Cava, Inferior
19.
Thromb Res ; 61(5-6): 489-99, 1991 Mar.
Article in English | MEDLINE | ID: mdl-2028451

ABSTRACT

Levels of major parameters of fibrinolysis were measured in 50 normal human fetuses between 19 and 39 weeks of gestation and compared to those of 50 healthy normal pregnant women and 30 adult controls. In fetuses, euglobulin clot lysis time (ECLT) was significantly shortened, plasminogen level was low and histidine-rich glycoprotein undetectable. While t-PA and u-PA levels were slightly lower than in adult controls, a significant decrease in PAI activity was demonstrated and no PAI-2 could be detected in fetal plasma. In contrast with these findings, the fibrinolytic equilibrium of pregnant women exhibited a prolonged ECLT and a strong increase in both PAI activity and PAI-2 antigen levels, while only a moderate elevation in u-PA and t-PA levels was measured.


Subject(s)
Fetal Blood/physiology , Fibrinolysis/physiology , Pregnancy/blood , Adult , Blood Proteins/analysis , Female , Fetal Blood/chemistry , Humans , Male , Plasminogen/analysis , Plasminogen/physiology , Plasminogen Activators/blood , Plasminogen Activators/physiology , Plasminogen Inactivators/blood , Proteins/analysis , Serum Globulins/analysis , Serum Globulins/physiology
20.
J Orthop Trauma ; 4(4): 371-5, 1990.
Article in English | MEDLINE | ID: mdl-2176235

ABSTRACT

A randomized double-blind study comparing the efficacy and safety of two different dosage regimens of a low-MW heparin, Enoxaparin (Lovenox) 20 mg twice (group A) or 40 mg once (group B), was carried out in 103 elderly patients with a fracture of the neck of the femur. Distal and proximal thrombosis occurred in 18.3% of patients in group A and in 10.4% in group B. No major hemorrhagic complication was observed, except for two hematomas in each group. This trial suggests that a total daily dose of 40 mg of Enoxaparin can be effective in the prevention of deep vein thrombosis in elderly surgically treated patients and does not involve a major risk of bleeding.


Subject(s)
Femoral Neck Fractures/surgery , Heparin, Low-Molecular-Weight/administration & dosage , Thromboembolism/prevention & control , Aged , Aged, 80 and over , Blood Loss, Surgical , Bone Nails , Double-Blind Method , Female , Fracture Fixation, Internal/instrumentation , Hip Prosthesis , Humans , Male , Phlebography , Plethysmography, Impedance , Postoperative Complications/prevention & control
SELECTION OF CITATIONS
SEARCH DETAIL
...